Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights
SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics ( Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the reporting period, the company achieved operating revenue ofRMB 168 million, ...
OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth
SHANGHAI, March 21, 2024 /PRNewswire/ -- On the evening of March 21st, OcuMension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "OcuMension" or the "Company") disclosed its 2023 annual performance report. The company achieved a total operating income ofRMB 246.4 million ...
Ocumension Releases its 2022 Interim Report with its core product Youshiying® being approved for marketing, continuously accelerating product commercialization
BEIJING, Aug. 26, 2022 /PRNewswire/ -- On August 26, 2022 (Beijing time), Ocumension Therapeutics (1477.HK) released its 2022 interim report. The Company's overall performance remained remarkable despite the fact that the pandemic caused considerable trouble in commercializing its ophthalmic prod...
Ocumension OT-401 (Product name: YUTIO), a treatment for chronic non-infectious uveitis officially approved for marketing by the National Medical Products Administration
BEIJING, June 23, 2022 /PRNewswire/ -- Ocumension Therapeutics （1477.HK）announced that the New Drug Application (NDA) for the core product in its pipeline, OT-401 (Sterile non-bioerodible intravitreal implant, Product name: YUTIO), was officially approved by the National Pharmaceutical Administ...
Ocumension Acquires all the Equity Interests in Two Ophthalmic Products Mainland China, Further Enhancing its Pipeline Strength
HONG KONG, Aug. 25, 2021 /PRNewswire/ -- Beijing time, August 24, 2021, Ocumension Therapeutics announced that it has entered into a product acquisition agreement with a leading global pharmaceutical company Novartis, pursuant to which the Company will acquire all the equity interests in two oph...
Ocumension Therapeutics Announces 2021 Interim Results
Company loss narrowed sharply by 96% Business Income Increased By More Than 26 Times Year-on-Year Core Product OT-401 Approval Imminent HONG KONG, Aug. 21, 2021 /PRNewswire/ -- The Chinese ophthalmology platform company,Ocumension Therapeutics ("Ocumension" or the "Company", together with its s...
Ocumension Therapeutics (1477.HK) Reports Revenue Growth in 2020, National Commercial Construction has been started to become outstanding
HONG KONG, March 20, 2021 /PRNewswire/ -- The Chinese ophthalmology platform company,Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, the "Group" ), (stock code: 1477.HK), announced its annual results for the year ended31 December 2020 today. Ocumension The...
Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases
HONG KONG, Oct. 30, 2020 /PRNewswire/ -- October 30, 2020, Ocumension Therapeutics (1477.HK) announced that the Company has entered into a collaboration and exclusive promotion agreement with Shandong Boan Biological Technology Co. Ltd., a wholly-owned subsidiary of Luye Pharma Group Ltd. to joi...
Ocumension Therapeutics Launches Initial Public Offering on Hong Kong Stock Exchange
SHANGHAI, July 10, 2020 /PRNewswire/ -- Ocumension Therapeutics ("Ocumension"), aChina-based ophthalmic pharmaceutical platform company, has today launched its Initial Public Offering (IPO) of the company's stock on The Stock Exchange of Hong Kong (HKEX). Ocumension plans to offer 105,930,000 shar...
